Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product, Qutenza (capsaicin)

 Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product, Qutenza (capsaicin)

Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product, Qutenza (capsaicin)

Shots:

  • Grunenthal acquired Averitas Pharma in all stocks transaction, gained the commercialization rights for Qutenza
  • The focus of the acquisition is to expand and strengthen its footprints in the markets of US
  • Qutenza (8% capsaicin) is an analgesic and is approved by the US FDA & EU for postherpetic neuralgia (PHN) & peripheral neuropathic pain indication in adults respectively

Click here to read full press release/ article | Ref: Grunenthal | Image: Glarus24

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post